Dbv Technologies SA
DBVT17.010USD
+0.010+0.06%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
465.45MMarket Cap
LossP/E TTM
More Details of Dbv Technologies SA Company
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
Dbv Technologies SA Info
Ticker SymbolDBVT
Company nameDbv Technologies SA
IPO dateMar 29, 2012
CEOTasse (Daniel)
Number of employees108
Security typeDepository Receipt
Fiscal year-endMar 29
AddressBatiment IRO
CityCHATILLON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryFrance
Postal code92320
Phone33155427878
Websitehttps://www.dbv-technologies.com/
Ticker SymbolDBVT
IPO dateMar 29, 2012
CEOTasse (Daniel)
Company Executives of Dbv Technologies SA
Name
Name/Position
Position
Shareholding
Change
Ms. Mailys Ferrere
Ms. Mailys Ferrere
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Michel De Rosen
Mr. Michel De Rosen
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Daniel Tasse
Mr. Daniel Tasse
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Pharis Mohideen, M.D.
Dr. Pharis Mohideen, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Julie O'Neill
Ms. Julie O'Neill
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Michael J. Goller
Mr. Michael J. Goller
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Kevin Trapp
Mr. Kevin Trapp
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Timothy E. (Tim) Morris, CPA
Mr. Timothy E. (Tim) Morris, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Adora Ndu, Pharm.D.
Dr. Adora Ndu, Pharm.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Ravi M. Rao, Ph.D.
Dr. Ravi M. Rao, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Mailys Ferrere
Ms. Mailys Ferrere
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Michel De Rosen
Mr. Michel De Rosen
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Daniel Tasse
Mr. Daniel Tasse
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Pharis Mohideen, M.D.
Dr. Pharis Mohideen, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Julie O'Neill
Ms. Julie O'Neill
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Michael J. Goller
Mr. Michael J. Goller
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 29
Updated: Sat, Nov 29
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
4.07%
Vivo Capital, LLC
2.93%
MPM BioImpact LLC
2.93%
Octagon Capital Advisors LP
2.83%
Yiheng Capital Management, L.P.
1.83%
Other
85.41%
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
4.07%
Vivo Capital, LLC
2.93%
MPM BioImpact LLC
2.93%
Octagon Capital Advisors LP
2.83%
Yiheng Capital Management, L.P.
1.83%
Other
85.41%
Shareholder Types
Shareholders
Proportion
Hedge Fund
10.03%
Venture Capital
4.48%
Investment Advisor/Hedge Fund
2.98%
Investment Advisor
2.20%
Research Firm
0.02%
Other
80.28%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
76
7.09M
19.73%
-828.86K
2025Q3
80
6.53M
6.35%
-713.35K
2025Q2
78
7.24M
2.87%
+4.76M
2025Q1
66
2.48M
4.09%
-1.72M
2024Q4
68
2.75M
4.37%
-480.40K
2024Q3
70
3.24M
24.42%
-194.92K
2024Q2
77
3.43M
26.03%
-367.31K
2024Q1
77
3.79M
25.92%
-1.19M
2023Q4
83
3.79M
25.33%
-662.60K
2023Q3
91
4.45M
30.68%
-162.47K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Baker Bros. Advisors LP
1.46M
4.07%
--
--
Sep 30, 2025
Vivo Capital, LLC
1.05M
2.93%
--
--
Sep 30, 2025
MPM BioImpact LLC
1.05M
2.93%
--
--
Sep 30, 2025
Octagon Capital Advisors LP
1.02M
2.83%
--
--
Sep 30, 2025
Yiheng Capital Management, L.P.
656.31K
1.83%
--
--
Sep 30, 2025
VR Adviser, LLC
555.82K
1.55%
+555.82K
--
Sep 30, 2025
Great Point Partners, LLC
378.59K
1.05%
+3.92K
+1.04%
Sep 30, 2025
Adage Capital Management, L.P.
345.93K
0.96%
-708.57K
-67.19%
Sep 30, 2025
Millennium Management LLC
337.86K
0.94%
+69.85K
+26.06%
Sep 30, 2025
Artisan Partners Limited Partnership
51.92K
0.14%
+51.92K
--
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ActivePassive International Equity ETF
0%
ActivePassive International Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Nov 13, 2024
Merger
5→1
Nov 13, 2024
Merger
5→1
Nov 13, 2024
Merger
5→1
Nov 13, 2024
Merger
5→1
May 17, 2024
Merger
2→1
May 17, 2024
Merger
2→1
Date
Type
Ratio
Nov 13, 2024
Merger
5→1
Nov 13, 2024
Merger
5→1
Nov 13, 2024
Merger
5→1
Nov 13, 2024
Merger
5→1
May 17, 2024
Merger
2→1
May 17, 2024
Merger
2→1
May 17, 2024
Merger
2→1
May 17, 2024
Merger
2→1
FAQs
Who are the top five shareholders of Dbv Technologies SA?
The top five shareholders of Dbv Technologies SA are:
Baker Bros. Advisors LP holds 1.46M shares, accounting for 4.07% of the total shares.
Vivo Capital, LLC holds 1.05M shares, accounting for 2.93% of the total shares.
MPM BioImpact LLC holds 1.05M shares, accounting for 2.93% of the total shares.
Octagon Capital Advisors LP holds 1.02M shares, accounting for 2.83% of the total shares.
Yiheng Capital Management, L.P. holds 656.31K shares, accounting for 1.83% of the total shares.
Baker Bros. Advisors LP holds 1.46M shares, accounting for 4.07% of the total shares.
Vivo Capital, LLC holds 1.05M shares, accounting for 2.93% of the total shares.
MPM BioImpact LLC holds 1.05M shares, accounting for 2.93% of the total shares.
Octagon Capital Advisors LP holds 1.02M shares, accounting for 2.83% of the total shares.
Yiheng Capital Management, L.P. holds 656.31K shares, accounting for 1.83% of the total shares.
What are the top three shareholder types of Dbv Technologies SA?
The top three shareholder types of Dbv Technologies SA are:
Baker Bros. Advisors LP
Vivo Capital, LLC
MPM BioImpact LLC
Baker Bros. Advisors LP
Vivo Capital, LLC
MPM BioImpact LLC
How many institutions hold shares of Dbv Technologies SA (DBVT)?
As of 2025Q4, 76 institutions hold shares of Dbv Technologies SA, with a combined market value of approximately 7.09M, accounting for 19.73% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 13.38%.
What is the biggest source of revenue for Dbv Technologies SA?
In --, the -- business generated the highest revenue for Dbv Technologies SA, amounting to -- and accounting for --% of total revenue.
